.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Farmers Insurance
Medtronic
Fish and Richardson
Colorcon
Federal Trade Commission
Chubb
Cantor Fitzgerald
Chinese Patent Office

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,265,720

« Back to Dashboard

Which drugs does patent 9,265,720 protect, and when does it expire?


Patent 9,265,720 protects EDLUAR and is included in one NDA. There has been one Paragraph IV challenge on Edluar.

This patent has nine patent family members in twelve countries.

Summary for Patent: 9,265,720

Title:Pharmaceutical formulations useful in the treatment of insomnia
Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Stockholm, SE), Bredenberg; Susanne (Uppsala, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:11/666,361
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Mylan Speciality LpEDLUARzolpidem tartrateTABLET;SUBLINGUAL021997-001Mar 13, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeMETHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
Mylan Speciality LpEDLUARzolpidem tartrateTABLET;SUBLINGUAL021997-002Mar 13, 2009ABRXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,265,720

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0423800.2Oct 27, 2004
PCT Information
PCT FiledOctober 26, 2005PCT Application Number:PCT/GB2005/004147
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/046041

Non-Orange Book Patents for Patent: 9,265,720

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,597,281Pharmaceutical formulations useful in the treatment of insomnia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,265,720

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office2340872► Subscribe
Spain2610469► Subscribe
United Kingdom0423800► Subscribe
Lithuania2340872► Subscribe
HungaryE030609► Subscribe
Japan2008517988► Subscribe
Japan5064226► Subscribe
Lithuania1807156► Subscribe
European Patent Office1807156► Subscribe
Cyprus1118414► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Teva
Healthtrust
McKinsey
Cerilliant
Merck
Queensland Health
Baxter
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot